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Abstract
Rationale: It is known that dopaminergic cell loss leads to
increased endogenous cannabinoid levels and CB1 receptor
density.
Objective: The aim of this study was to evaluate the
influence of dopaminergic cell loss, induced by injection
of 6-hydroxydopamine, on the effects exerted by cannabi-
noid agonists on neuron activity in the subthalamic nucleus
(STN) of anesthetized rats.
Results: We have previously shown that Δ
9-tetrahydrocan-
nabinol (Δ
9-THC) and anandamide induce both stimulation
and inhibition of STN neuron activity and that endocanna-
binoids mediate tonic control of STN activity. Here, we
show that in intact rats, the cannabinoid agonist WIN
55,212-2 stimulated all recorded STN neurons. Conversely,
after dopaminergic depletion, WIN 55,212-2, Δ
9-THC, or
anandamide inhibited the STN firing rate without altering
its discharge pattern, and stimulatory effects were not
observed. Moreover, anandamide exerted a more intense
inhibitory effect in lesioned rats in comparison to control rats.
Conclusions: Cannabinoids induce different effects on the
STN depending on the integrity of the nigrostriatal pathway.
These findings advance our understanding of the role of
cannabinoids in diseases involving dopamine deficits.
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Introduction
Parkinson's disease (PD) is a neurological disorder charac-
terized by a progressive degeneration of nigral dopaminer-
gic neurons projecting to the striatum (reviewed in Blandini
et al. 2000). Numerous studies have suggested that altered
neuronal output from the subthalamic nucleus (STN) in the
dopamine-deficient state is central to the pathophysiology
of PD (Benazzouz et al. 2000). An elevated discharge rate
and a preponderant bursting pattern of STN neurons have
been reported in experimental models of PD (Bergman et
al. 1994; Hassani et al. 1996;V i l ae ta l .2000; Magill et al.
2001;B r e i te ta l .2007); indeed, some STN cells have been
found to exhibit a rhythmic activity which is highly
correlated with limb tremor in Parkinsonian patients (Levy
et al. 2000; Magariños-Ascone et al. 2000). The importance
of the STN in the etiopathology of movement disorders is
also evidenced by the effective therapeutic effects of surgical
lesions, high frequency electrical stimulation, or pharmaco-
logical blockade in rats (Piallat et al. 1999; Burbaud et al.
1995), in Parkinsonian monkeys and in PD patients
(Limousin et al. 1995), where decreasing the activity of the
STN ameliorates the major motor symptoms and reverses
some of the electrophysiological and metabolic consequen-
ces of dopamine depletion (Hamani et al. 2004).
The endocannabinoid system appears to be implicated in
the central regulation of motor functions. CB1 receptors
and endocannabinoids are abundant in the basal ganglia,
which comprise areas known to be involved in motor
control (Julian et al. 2003; Bisogno et al. 1999; Hohmann
and Herkenham 2000; Mackie 2005). Indeed, endogenous,
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DOI 10.1007/s00213-010-2043-0plant-derived, and synthetic cannabinoids have potent, mostly
inhibitory effects on motor activity (Crawley et al. 1993;F r i d e
and Mechoulam 1993; Smith et al. 1994;R o m e r oe ta l .2002).
On the other hand, it has been found that CB1 receptor
binding and endocannabinoid levels are increased in the
basal ganglia, both in experimental models of parkinson-
ism (Romero et al. 2000; Gubellini et al. 2002; Maccar-
rone et al. 2003;G o n z a l e ze ta l .2006)a n di nP a r k i n s o n i a n
patients (Lastres-Becker et al. 2001;P i s a n ie ta l .2005).
However, the issue is far from clear as other authors have
also reported no changes (Herkenham et al. 1991), reduced
levels (Silverdale et al. 2001), or dependency of levels on
chronic L-dopa co-treatment (Zeng et al. 1999).
Therefore, it has been suggested that cannabinoid modula-
t i o nm a yr e p r e s e n ta ne f f e c t i v et o o lt ob ei n c l u d e di nn o v e l
therapeutictreatmentsofmotordisturbances(Consroe1998;D i
Marzo et al. 2004;B r o t c h i e2003;P a c h e re ta l .2006). Thus,
the aim of the present study was to characterize STN neuron
activity and to examine the effect of the cannabinoids
Δ
9-tetrahydrocannabinol (Δ
9-THC), anandamide, and of the
synthetic cannabinoid receptor agonist WIN 55,212-2, in
6-hydroxydopamine (6-OHDA)-lesioned rats which, due to
dopamine depletion, represent a model of PD.
Materials and methods
Male albino Sprague–Dawley rats weighing 250–350 g
were housed under controlled environmental conditions
(22°C and a 12-h light/dark cycle) with free access to food
and water. All experiments complied with international
guidelines concerning the ethical use of animals specified
in the European Communities Council Directive of 24
November 1986 (86/609/EEC).
6-OHDA-induced lesion
Animals were anesthetized with chloral hydrate (400 mg/
kg, i.p.) and were placed in a stereotaxic frame. Thirty
minutes before stereotaxic lesioning, rats were pretreated
with desipramine (25 mg/kg, i.p.) in order to protect
noradrenergic terminals from 6-OHDA toxicity and with
pargyline (50 mg/kg, i.p.) to inhibit monoamine oxidases.
6-OHDA was unilaterally injected into the right nigrostria-
tal pathway at a site just anterior to the substantia nigra and
dorsal to the medial forebrain bundle (coordinates, 4.4 mm
anterior to the lamboid suture, 1.2 mm lateral to the midline
suture, and 8.2 mm ventral to the cortical surface (Paxinos
and Watson 1986)). Each rat received an injection of 4 μlo f
6-OHDA (2 μg/μl in saline containing 0.02% ascorbic
acid). Electrophysiological experiments were performed
4 weeks after the lesion. Lesion severity was evaluated
after all experimental procedures by immunohistochemistry.
Electrophysiology
Rats were anesthetized with urethane (1.2 g/kg, i.p.), a
cannula was inserted into the trachea, and the right jugular
vein was cannulated for additional drug administration.
Animal body temperature was maintained at ~37°C for the
entire duration of the experiment by means of a heating pad
connected to a rectal probe. The rat was placed in a
stereotaxic frame with its head secured in a horizontal
orientation. The skull was exposed, and a 3-mm burr hole
was drilled over the right STN. For intracerebroventricular (i.c.
v.) drug administration, a 23-gauge steel catheter was inserted
into the right lateral ventricle, 1.0 mm caudally and 1.3 mm
laterally to Bregma, at a depth of 4–5m mf r o mt h es k u l l
surface, and fixed with dental cement. The intraventricular
position of the catheter was controlled by inspection of the level
of an air bubble in a plastic tube connected to the cannula.
The recording electrode, consisting of an Omegadot
single glass micropipette, pulled with an electrode puller
(Narishige Scientific Instrument Lab., PE-2, Japan), was
broken back to a tip diameter of 1–2.5 μm under a light
microscope and filled with 2% Pontamine Sky Blue in
0.5% sodium acetate. The electrode was placed 3.2–3.5 mm
posterior to Bregma, 2.2–2.7 mm lateral to midline, and 7–
8 mm ventral to the dura mater (Paxinos and Watson 1986).
The extracellular signal from the electrode was amplified
with a high-input impedance amplifier, and then monitored
on an oscilloscope and on an audio monitor. All recorded
STN neurons exhibited a biphasic waveform and a pulse
width of 1.0 to 1.5 ms (as described by Hollerman and
Grace 1992). Neuronal spikes were digitized using com-
puter software (CED micro 1401 interface and Spike2
software, Cambridge Electronic Design, UK). The basal
firing rate was recorded for 3–5 min. Only one STN cell
was pharmacologically studied in each animal.
Data regarding the firing patterns of the discriminated
STN neurons were analyzed off-line using the Spike2
software, and the following parameters were calculated:
firing rate and coefficient of variation (the latter is a
measure of firing regularity and is defined as the percentage
ratio of the standard deviation to the mean interval
histogram). Using the NeuronFit program (NorayBio
Informatics), three different firing patterns could be
distinguished according to the method of Kaneoke and
Vitek (1996), based on the concept of density distribution
and on a statistically rigorous definition of the firing
pattern: (1) a tonic firing pattern characterized by a
symmetrical density distribution histogram, (2) a random
firing pattern characterized by a Poisson distribution, and
(3) a bursting firing pattern characterized by a distribution
histogram which is significantly different (p<0.05) to a
Poisson distribution, presenting a significantly positive
skewness (p<0.05) of the density distribution histogram
380 Psychopharmacology (2011) 214:379–389and a minimum of four spikes per burst. The analyzed
spike-trains lasted more than 120 s and contained at least
300 spikes.
Experimental data were analyzed using GraphPad Prism
software (v. 4.0, GraphPad Software, Inc). Data were
reported in terms of mean±SEM. Statistical significance
was assessed by the paired Student's t test for firing rate and
coefficient of variation, to compare basal parameters before
and after drug administration, or by the one-way repeated
measures analysis of variance (ANOVA), followed by the
Newman–Keuls test for the effects of the drugs on STN
neurons. To compare the effects of Δ
9-THC or anandamide
in intact and lesioned groups, a two-way repeated measures
ANOVAwas used. Firing patterns were compared using the
Chi-squared (χ
2) test. The level of statistical significance
was considered to be p<0.05.
Histological verifications
Upon concluding experiments, a 5-μA cathodal current was
passed through the recording electrode, thereby depositing
a discrete spot of Pontamine Sky Blue at the recording site.
Rats were heavily anesthetized and perfused transcardially
with phosphate buffer saline (PBS) followed by 4–5%
formaldehyde in PBS. The brains were removed and then
cryoprotected in 20% sucrose in PBS before being frozen
at −80°C.Coronal sections(50μm)were cutusinga cryotome
through the striatum, the STN, and the mesencephalon.
All sections containing the STN were subsequently
stained with Neutral Red to determine the location of
Pontamine Sky Blue dots, and only recordings from rats
showing this mark in the STN were further considered.
Another series of brain sections was used for free-floating
immunohistochemistry of tyrosine hydroxylase (TH) to
examine the effect of dopaminergic denervation on the
striatum and the substantia nigra pars compacta (SNpc) as
described by Bilbao et al. (2006). Slices were incubated in
mouse anti-TH antibody, which was subsequently detected
using a biotinylated horse anti-mouse antiserum. Both
immunoreagents were diluted in PBS. Secondary antibodies
were labeled with peroxidase using an ABC kit (PK 6100,
Vector, Burlingame, CA, USA). The presence of bound
peroxidase was finally manifested using a commercial kit
(Vector VIP®, SK 4600, Vector, Burlingame, CA, USA).
Subsequently, sections were rinsed, mounted, dehydrated,
and coverslipped. The extent of the lesion was verified by
the density of striatal dopaminergic innervation based on
TH-immunoreactivity. Images of three striatal sections were
captured using a digital camera. These images were taken
rostrocaudally, and mean optical density (OD) was
measured using the NIH image analysis software,
ImageJ. For each slide, the whole striatum was delimited,
and its optical TH-immunoreactivity density was
expressed as a percentage of that of the contralateral
intact side with the background in the cortex set as 0%
and the contralateral intact striatum set as 100%.
Drugs
Anandamide (N-(2-hydroxyethyl)-5Z,8Z,11Z,14Z-eicosate-
traenamide) was obtained from Tocris (UK). Delta-9-
tetrahydrocannabinol (Δ
9-THC) was a generous gift from
GW Pharmaceuticals Ltd. (Salisbury, UK) and rimonabant
([N-piperidino-5(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-
methylpyrazolel -carboxamide) from Sanofi-Synthelabo S.
A. (France). WIN 55,212-2, 6-OHDA, desipramine,
pargyline, chloral hydrate, and urethane were obtained from
Sigma (Madrid, Spain). Anandamide was dissolved in
Tocrisolve™ 100; Δ
9-THC in ethanol solution; WIN
55,212-2 and rimonabant in 1:1:18 cremophor/ethanol/saline
solution; 6-OHDA in distilled water containing 1 mg/ml
ascorbate and chloral hydrate; and urethane, desipramine,
and pargyline were prepared in 0.9% saline. Drugs were
prepared on the day of the experiment.
Results
Firing properties of STN neurons in intact
and 6-OHDA-lesioned rats
Allrecordedneuronsexhibitedthetypicalelectrophysiological
characteristicsofSTNneurons,includingabiphasicwaveform
and a duration of 1.0–1.5 ms. The mean basal firing rate of
STN neurons in 6-OHDA-lesioned rats was significantly
higher than that found in intact rats (14.0±1.2 vs. 7.1±
0.5 Hz, n=21 and n=60, respectively, p<0.0001, Student's
t-test; Fig. 1a, d). The coefficient of variation also increased
following lesion (83.5±10.6 vs. 60.6±3.2, p<0.01, Student's
t test; Fig. 1b). Consistently, STN neurons in lesioned rats
exhibited more bursting discharge than those in intact
rats (χ
2=11.58, df=2, p<0.01; Fig. 1c). Thus, in intact
rats, 71% of STN neurons exhibited a tonic-firing pattern,
23% a bursting pattern, and 6% a random pattern. In
contrast, in lesioned rats, 36% of STN neurons exhibited a
tonic-firing pattern, while 64% presented a bursting firing
pattern. These observed changes are consistent with the
generally accepted idea that the STN is hyperactive in the
Parkinsonian state (Bergman et al. 1994; Hassani et al.
1996;V i l ae ta l .2000;N ie ta l .2001; Magill et al. 2001).
Effect of WIN 55,212-2 on STN neurons in intact
and 6-OHDA-lesioned rats
We next studied the effect of the synthetic cannabinoid
agonist WIN 55,212-2 (31.25–250 μg/kg, i.v., doubling
Psychopharmacology (2011) 214:379–389 381doses) on the electrical activity of STN neurons in intact
and lesioned rats (one cell per rat). In intact rats, WIN
55,212-2 increased the firing rate of STN neurons (maximal
effect, 83±27%; F4,39=27.86, p<0.0001, one-way repeated
measures ANOVA; n=8; Fig. 2a, c). This agonist reduced
the coefficient of variation (maximal effect, 26±8%; F4,39=
3,10, p<0.05, one-way repeated measures ANOVA;
Fig. 2d), and firing was essentially of the bursting discharge
type (relative amount of neurons exhibiting bursting pattern
significantly increased to 100%; χ
2=4.29, df=1, p<0.05).
In contrast, in lesioned rats, WIN 55,212-2 reduced the
firing rate of STN neurons (maximal effect, 51±13%;
F3,19=5.89,p<0.01, one-way repeated measures ANOVA;
n=8; Fig. 2b, c), whereas the firing pattern and firing
regularity were unaltered (p>0.05, χ
2 test and one-way
repeated measures ANOVA, respectively; Fig. 2d).
As shown in Fig. 2a, b, the effects produced by WIN
55,212-2 in intact and lesioned rats were reversed by the
CB1 antagonist rimonabant (2,000 μg/kg, i.v.). Firing rates
before and after rimonabant were 8.08±2.41 and 5.26±
0.87 spikes/s (paired t test, p>0.05, n=3) and 11.52±2.15
and 9.09±2.04 spikes/s (paired t test, p>0.05, n=3),
respectively).
Effect of Δ
9-THC and anandamide on STN neurons
in 6-OHDA-lesioned rats
We next examined the effects of the natural cannabinoid Δ
9-
THC and the endocannabinoid anandamide on STN neurons
in 6-OHDA-lesioned rats. As we have previously shown
(Morera-Herreras et al. 2010a, b), administration of Δ
9-THC
(250–2,000 μg/kg, i.v.) or anandamide (50, 100, and 150 μg,
i.c.v.) induced two opposite effects on STN neuron activity
in intact rats (Fig. 3). On the one hand, Δ
9-THC increased
the firing rate (maximal effect, 102±35%, F4,49=13.74,
p<0.0001, one-way repeated measures ANOVA; n=10),
the regularity (the coefficient of variation decreased;
maximal effect, 31±6%, F4,49=7.72, p<0.0001, one-way
repeated measures ANOVA; n=10), and the burst firing of
STN neurons. On the other hand, Δ
9-THC induced a
decrease in the basal firing rate (maximal effect, 64±5%,
F4,24=4.91,p<0.01, one-way repeated measures ANOVA;
n=5) and in the regularity of neuron activity, i.e., the
coefficient of variation increased (maximal effect, 101±
35%, F4,24=4.77, p<0.01, one-way repeated measures
ANOVA; n=10), but without altering the firing pattern
(Fig.3a, b). Similarly, anandamide induced an increase in the
firing rate (maximal effect, 32±8%, F3,19=13.59,p<0.0001,
one-way repeated measures ANOVA; n=8) and in burst
firing, but not in the regularity of neuron activity (the
coefficient of variation was unaltered; maximal effect, 2±
16%, F3,19=0.51, p>0.05, one-way repeated measures
ANOVA; n=8). Anandamide also induced a decrease in
the basal firing rate (maximal effect, 31±5%, F3,231=30,15,
p<0.0001, one-way repeated measures ANOVA; n=8) and
in the regularity of neuron activity (the coefficient of
variation increased; maximal effect, 49±205%, F3,31=4.53,
p<0.05, one-way repeated measures ANOVA; n=8), but
without altering the firing pattern (Fig. 3c, d).
However, after 6-OHDA-lesion, Δ
9-THC administration
induced a decrease in the basal firing rate of all STN
neurons recorded (maximal effect, 57±13%; F4,44=9.38,
Fig. 1 Histograms illustrating the mean firing rate (a) and mean
coefficient of variation (percent) (b) of STN neurons recorded in intact
(white square) and 6-OHDA-lesioned (black square) rats; **p<0.01;
***p<0.001 vs. corresponding basal value (Student's t test). Distribu-
tion of firing patterns (c) of STN neurons in intact and lesioned rats;
**p<0.01 vs. intact group (Chi-squared (χ
2) test). d Samples of
spontaneous spiking activity recorded in the STN of an intact (top) and
a lesioned rat (bottom). Vertical lines represent spike events. Note the
increase in the basal firing rate as well as in the bursting discharge in
lesioned rats
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Fig. 3a), whereas the firing pattern and the regularity of
neuron firing remained unaltered (p>0.05, χ
2 test and one-
way repeated measures ANOVA, respectively; Fig. 3b). No
difference in this inhibitory effect was observed between
the intact and lesioned groups (F1,59=0.20, p=0.66, two-way
ANOVA; Fig. 3a). Similarly, anandamide reduced the firing
rate of all STN neurons recorded (maximal effect, 84±10%;
F3,19=9.55, p<0.01, one-way repeated measures ANOVA;
n=5;Fig.3c), whereas the firing pattern and the regularity of
neuron firing were unaltered (p>0.05, χ
2 test and one-way
repeated measures ANOVA, respectively; Fig. 3d). More-
over, in this case, the inhibitory effect induced by ananda-
mide in lesioned rats was significantly higher than that
observed in the intact group (two-way ANOVA, F1,41=
73.98, p<0.0001; Fig. 3c).
In all recorded neurons, the CB1 receptor antagonist
rimonabant (2 mg/kg, i.v.) restored the firing rates to basal
values.Thus, the firingrates beforeand after rimonabantwere
14.91±1.83 and 15.64±3.04 spikes/s (paired t test, p>0.05,
n=7) and 14.32±2.62 and 11.19±1.89 spikes/s (paired t test,
p>0.05,n=8) for neurons in lesioned rats in which Δ
9-THC
and anandamide effects were studied, respectively.
Recording site and tyrosine hydroxylase immunostaining
After the electrophysiological experiments had been carried
out, Pontamine Sky Blue dots were localized in Neutral Red
stainedSTNsections,revealingthatallrecordedneuronsfrom
6-OHDA-lesioned rats and those that were recorded before
and after WIN 55,212-2 administration to intact rats were
located quite homogeneously over the entire STN (Fig. 4).
Conversely, as we have previously shown (Morera-Herreras
et al. 2010a, b), neurons inhibited by Δ
9-THC or ananda-
mide are predominantly located in the dorsolateral portion of
the rostral STN, whereas stimulated neurons are located in
the ventromedial portion of the caudal STN.
The effectiveness of dopaminergic depletion by means
of 6-OHDA lesion was verified by TH immunohistochem-
istry. All 6-OHDA lesioned animals included in the study
showed >95% reduction (remaining dopaminergic fibers
2.9±0.5%) in TH-fiber density in the striatum on the side
ipsilateral to the lesion (Fig. 5). The precision of this
method to quantify the degree of the lesion is confirmed by
the linear relationship between the number of TH-
immunoreactive neurons in the SNpc and optical density
in the striatum (Bilbao et al. 2006). Thus, further cell
Fig. 2 Representative firing rate
histograms illustrating the effect
of intravenous (i.v.) administra-
tion of cumulative doses of WIN
55,212-2 (31.25–250 μg/kg, i.v.,
doubling doses) on STN neuro-
nal activity in intact (a) and
6-OHDA-lesioned rats (b). Both
stimulatory and inhibitory
effects were reversed by admin-
istration of the CB1 receptor
antagonist rimonabant
(250–2,000 μg/kg, i.v.). c The
mean firing rate and (d) the
mean value of the coefficient of
variation of STN neurons fol-
lowing WIN 55,212-2 adminis-
tration (31.25–250 μg/kg, i.v.,
doubling doses) in intact (white
circle; n=8) and lesioned rats
(black circle; n=8). Data are
expressed as mean±SEM; *p<
0.05; **p<0.01; ***p<0.001
vs. corresponding basal value
(one-way repeated measures
ANOVA followed by the
Student–Newman–Keuls test)
Psychopharmacology (2011) 214:379–389 383counting in the SNpc was not necessary to verify lesion
severity.
Discussion
The cannabinoid agonists Δ
9-THC and anandamide are
known to exert two opposite effects, i.e., inhibition and
stimulation, on STN neurons through CB1 receptors located
in the globus pallidus (GP) and cerebral cortex, respectively,
by mechanisms involving GABA and excitatory amino acids
(Morera-Herreras et al. 2010a, b). The present study further
extends these results by showing that dopaminergic cell loss,
induced by injection of 6-OHDA, abolishes or reverses the
stimulatory effect of cannabinoid agonists on STN neurons,
and enhances the effect of the endocannabinoid anandamide
(see Table 1). These changes in cannabinoid response in
lesioned rats can in principle be attributed to dopaminergic
cell loss. Rotational behavior tests (involving apomorphine
and/or amphetamine administration) were not performed in
order to avoid pharmacological interactions.
The classical model of basal ganglia functionality
proposed by Alexander and Crutcher (1990) states that
under normal conditions, the activity of the STN is
regulated primarily by an inhibitory GABAergic projection
from the external segment of the GP (Parent and Hazrati
1995) and by excitatory glutamatergic projections from
multiple cortical areas (Fujimoto and Kita 1993; Maurice et
al. 1998). According to this model, dopaminergic deficien-
cy associated with the Parkinsonian state leads to reduced
inhibition from the GP pathway, leading to disinhibition
of the STN, resulting in its hyperactivity. The GP and the
cerebral cortex are known to express moderate to high
levels of CB1 receptor (Julian et al. 2003). Activation of
these receptors inhibits the release of GABA and glutamate
(Szabo et al. 2000; Gerdeman and Lovinger 2001;
Wallmichrath and Szabo 2002), which can result in the
stimulation or inhibition of STN, respectively. In 6-
OHDA-lesioned animals, the pallido-GABAergic influence
on the STN is reduced (Bergman et al. 1998; Hassani et al.
1996). The absence of a stimulatory effect of cannabinoids in
6-OHDA-lesioned animals could therefore be understood in
Fig. 3 Effects of cumulative doses of Δ
9-THC and anandamide on
STN neurons in intact and 6-OHDA-lesioned rats. a The mean firing
rate and (b) the mean value of the coefficient of variation of STN
neurons following Δ
9-THC administration (250–2,000 μg/kg, i.v.,
doubling doses) in lesioned rats (black circle; n=9) and in intact rats,
where two opposite effects were found: an increase (white circle; n=
10) and a decrease in firing rate (black square; n=5). c The mean
firing rate and (d) the mean value of the coefficient of variation of
STN neurons following anandamide administration (50–150 μg, i.c.v.)
in lesioned rats (black circle; n=5) and in intact rats, where two
opposite effects were also observed: an increase (white circle; n=8)
and a decrease in firing rate (black square; n=8). Data are expressed as
mean±SEM. *p<0.05; **p<0.01; ***p<0.001 vs. corresponding
basal value (one-way repeated measures ANOVA followed by the
Student–Newman–Keuls test)
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and cannabinoid effects would be limited to their inhibition
of glutamatergic neurotransmission (i.e., the presence of
inhibition only), since the impact of the cortex on activity of
the STN is even greater following depletion of dopamine
( M a g i l le ta l .2001). In line with this hypothesis, it has
been suggested that endocannabinoid-mediated depression
of indirect pathway synapses plays a critical role in the
control of movement, since the endocannabinoid-mediated
long-term depression of striato-pallidal medium spiny
neurons (indirect pathway), which occurs in intact animals,
is absent in PD animal models and is rescued by inhibitors of
endocannabinoid degradation, which also reduce motor
deficits (Kreitzer and Malenka 2007). Our results also
corroborate those of Sañudo-Peña et al. (1998) who found
that 6-OHDA-lesioned rats exhibited greater contralateral
turning behavior in response to intranigral infusion of a
cannabinoid agonist than intact rats and suggested that this
could be due to the blockage of a hyperactive subthalamic
input to the substantia nigra.
Another novel finding of the present study was that the
synthetic cannabinoid agonist WIN 55,212-2 induced an
exclusively stimulatory effect on STN neurons in intact
rats, whereas the others cannabinoids used produced
stimulation or inhibition. The stimulatory effect seems to
be mediated by the same receptor, since the maximal
stimulatory effect induced by WIN 55,212-2 or Δ
9-THC
was similar and higher than that due to anandamide
(probably underestimated due to concomitant degradation
by fatty acid amide hydrolase (Di Marzo et al. 1994)). In
line with binding studies (Pertwee 1997), the results show
that WIN 55,212-2 was more potent than the natural
agonist, and in all cases, the effect of this synthetic
cannabinoid was reversed by the CB1 cannabinoid receptor
antagonist. The difference between the effect induced by
WIN 55,212-2 and those previously shown with Δ
9-THC
Fig. 4 Histological verification
of the recording site in the
subthalamic nucleus (STN). a
Schematic illustration of the
recording location of STN
neurons. Image modified from
Paxinos and Watson (1986),
with permission from Elsevier. b
Pontamine Sky Blue dots in
Neutral Red-stained STN
sections at different anatomical
levels are homogenously
distributed within the nucleus
(the examples correspond to
recorded neurons in 6-OHDA-
lesioned rats and in intact rats in
which WIN 55,212-2 was
administered). Scale bar,4 0μm
Psychopharmacology (2011) 214:379–389 385and anandamide may be due to the different sensitivity to
WIN 55,212-2 of CB1 receptors mediating the inhibition of
glutamate release or GABA release, as has been proposed
by other authors (Hoffman and Lupica 2000; Hajos and
Freund 2002; Hoffman et al. 2007). Corroborating this
possibility, it has been reported that in the hippocampus, the
receptor mediating the inhibition of glutamate release is less
sensitive to WIN 55,212-2 than the CB1 receptor mediating
the inhibition of GABA release (Hajos and Freund 2002).
Curiously, the inhibitory effect induced by anandamide
was higher in 6-OHDA-lesioned rats than in intact rats.
This could be due to overactivity of endocannabinoid
transmission in the basal ganglia, which has been reported
in 6-OHDA-lesioned or reserpine-treated rat models of PD.
Thus, an increase in the tissue levels of endocannabinoids
and CB1 receptors, as well as a decreased rate of
endocannabinoid transport and degradation by the fatty
acid amide hydrolase, has been found (Gubellini et al.
2002). Our data indicate that the sensitivity of CB1
receptors remains unaltered after lesion because the
magnitude of the effects after administration of Δ
9-THC
or WIN 55,212-2 in intact and 6-OHDA-lesioned rats is
similar. Therefore, the increased effect induced by ananda-
mide in 6-OHDA-lesioned rats is more likely due to
changes in the activity of FAAH. In keeping with this idea,
we have previously shown that the blockage of endocanna-
binoid degradation by FAAH inhibition enhances the
effects of anandamide on STN neurons in control rats
(Morera-Herreras et al. 2010b).
The present results, corroborating the findings of many
other studies, show that the STN is overactive in 6-OHDA
lesioned rats (Bergman et al. 1994; Hassani et al. 1996; Vila
et al. 2000; Ni et al. 2001; Magill et al. 2001). A decrease
in STN hyperactivity is thought to underlie the efficacy of
anti-Parkinsonian treatments. In fact, STN inactivation, by
lesioning or implanting electrodes for deep stimulation,
leads to an alleviation of the cardinal Parkinsonian features
and of levodopa-induced dyskinesia in PD patients (Damier
2009). Several findings indicate that pharmacological
modulation of the cannabinoid system may constitute a
Fig. 5 Representative tyrosine
hydroxylase (TH) immunostain-
ing in the striatum (a, b) and
substantia nigra (c, d) following
6-OHDA infusion into the right
nigrostriatal pathway. In control
rats (a, c), TH immunostaining
was intense and comparable
between both sides. In rats
microinfused unilaterally with
6-OHDA into the right
nigrostriatal pathway (b, d), a
substantial loss of TH
immunostaining was observed
in each area (right side)
compared with the contralateral
side (left side)
Table 1 Summary of changes induced by cannabinoids on electrophysiological parameters of subthalamic neurons in control and 6-OH
dopamine-lesioned (6OH-DA) rats
WIN 55,212-2 Δ
9-THC Anandamide
Control 6-OHDA Control 6-OHDA Control 6-OHDA
Firing rate ↑↓ ↓ /↑↓ ↓ /↑↓ ↓
Coefficient of variation ↓ = ↑/↓ = ↑/= =
Burst firing ↑ == / ↑ == / ↑ =
Cells were recorded for 180 s before and after drug administration
↑ increase, ↓ decrease, = no change refer to changes in firing parameters after drug administration with respect to basal values
386 Psychopharmacology (2011) 214:379–389new approach for the treatment of PD. However, results are
still somewhat confusing. Thus, clinical trials have demon-
strated that the cannabinoid receptor agonist nabilone
significantly reduces L-dopa-induced dyskinesia in Parkin-
sonian patients (Sieradzan et al. 2001), whereas other
clinical trials involving either agonists or antagonists have
not found any effect on dyskinesias or parkinsonism
(Frankel et al. 1990; Carroll et al. 2004; Mesnage et al.
2004). Results from animal studies are similarly confusing.
For instance, it has been shown that cannabinoid agonists
alleviate motor impairment seen in animal models of PD
(Gilgun-Sherki et al. 2003; Kreitzer and Malenka 2007) and
delay or reduce the incidence of L-dopa-induced dyskinesias
(Fox et al. 2002; Morgese et al. 2007). Nevertheless,
administration of a CB1 receptor antagonist was also found
to lead to a decrease in motor disturbances associated with
dopamine loss and L-dopa-induced dyskinesias (El-Banoua
et al. 2004; Fernandez-Espejo et al. 2005; Gonzalez et al.
2006). The results of the present study may contribute to
resolving these paradoxes, by showing that cannabinoids
induce different effects on the STN depending on the
integrity or degree of compromise of different components
of the dopaminergic system.
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